Guest Commentary

Guest Commentary

The Present and Future Multiple Myeloma Landscape

The rapid pace of drug approvals in multiple myeloma (MM) shows no sign of abating. In the past two years, the U.S. Food and...
Advertisement

Current Issue

July 2017, Volume 3, Issue 8

This issue features an interview with the FDA's Richard Pazdur, highlights from the 2017 ASCO Annual Meeting, a debate about minimal residual disease in myeloma, and more.